TapImmune, Inc. (TPIV) Stock Faces Higher Risks Forward After Forming Double Bottom

May 21, 2018 - By reb123z

TapImmune, Inc. (NASDAQ:TPIV) Logo

The chart of TapImmune, Inc. (TPIV) shows a double bottom with $3.62 target or 3.00 % below today’s $3.73 share price. The 9 months chart pattern indicates high risk for the $39.90M company. It was reported on May, 21 by Finviz.com. If the $3.62 price target is reached, the company will be worth $1.20 million less. Double bottoms are rare but powerful chart patterns.

The stock increased 1.20% or $0.04 during the last trading session, reaching $3.73. About 95,405 shares traded or 90.87% up from the average. TapImmune, Inc. (NASDAQ:TPIV) has declined 26.26% since May 21, 2017 and is downtrending. It has underperformed by 37.81% the S&P500.

More important recent TapImmune, Inc. (NASDAQ:TPIV) news were published by: Prnewswire.com which released: “TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform” on May 16, 2018, also Prnewswire.com published article titled: “TapImmune to Present at 2018 NYC Oncology Investor Conference”, Bizjournals.com published: “Merger takes Jacksonville immunotherapy company to Houston” on May 15, 2018. More interesting news about TapImmune, Inc. (NASDAQ:TPIV) was released by: Seekingalpha.com and their article: “TapImmune’s (TPIV) Proposed Merger with Marker Therapeutics (Transcript)” with publication date: May 18, 2018.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company has market cap of $39.90 million. It specializes in the development of immunotherapies targeting womenÂ’s cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. It currently has negative earnings. The companyÂ’s peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patientÂ’s killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.